

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | The proto-oncogene c-myc encodes a transcription factor c-Myc, which is of great importance in controlling cell growth and vitality[1]. The heterodimerization of c-Myc with Myc-associated factor X (MAX) plays a critical role in the proliferation, transformation, and apoptosis. Mycro3 is a small-molecule inhibitor of Myc-Max dimerization and also inhibit c-Myc/Max/DNA binding[2]. c-Myc has become an interesting and feasible target for novel therapies of a variety of human malignancies related to c-Myc, Mycro3 may be a novel and effective therapeutic agents to treat cancer. Mechanism: Mycro-3 is shown to bind one of the three discrete binding sites on the c-Myc bHLH-Zip domain[3]. |
| Concentration | Treated Time | Description | References | |
| CD8 T cells | above 100 μM | 2 days | Mycro3 had almost no effect on CD8 T cells at those concentrations. When the Mycro3 concentration was increased by 10-fold to above 100 μM, the metabolic activities of all T cell subsets were inhibited | Cell Mol Immunol. 2022 Sep;19(9):1030-1041 |
| AsPC-1 cells | 5000 nM | 4 hours | To evaluate the effect of Mycro3 on the migration and invasion capabilities of pancreatic cancer cells. Results showed that Mycro3 significantly reduced the migratory and invasive abilities of AsPC-1 cells. | Cancer Cell Int. 2021 Dec 14;21(1):670 |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | B16F10 mouse melanoma model | Intraperitoneal injection | 100 mg/kg body weight | Once every 3 days for a total of four cycles | Mycro3 significantly reduced tumor volume, increased immune cell infiltration in tumors, and sensitized tumors to anti-PD-1 treatment by modulating the tumor microenvironment, including decreasing Treg cells and increasing CD8 T cells | Cell Mol Immunol. 2022 Sep;19(9):1030-1041 |
| SCID mice | Metastatic mouse model | Intragastric administration | 100 mg/kg/d | Once daily | To evaluate the inhibitory effect of Mycro3 on pancreatic cancer cell metastasis in vivo. Results showed that Mycro3 alone did not show significant anti-metastatic effects in vivo. | Cancer Cell Int. 2021 Dec 14;21(1):670 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.90mL 0.38mL 0.19mL |
9.49mL 1.90mL 0.95mL |
18.98mL 3.80mL 1.90mL |
|
| CAS号 | 944547-46-0 |
| 分子式 | C24H17ClF2N6O4 |
| 分子量 | 526.88 |
| SMILES Code | CCOC(=O)C1=C(NC(=O)C2=NN3C(=C2)N=C(C=C3C(F)(F)Cl)C2=CC=CO2)N(N=C1)C1=CC=CC=C1 |
| MDL No. | MFCD03409284 |
| 别名 | |
| 运输 | 蓝冰 |
| InChI Key | YPPNLSKYXDXQGD-UHFFFAOYSA-N |
| Pubchem ID | 1045147 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, store in freezer, under -20°C |
| 溶解方案 |
DMSO: 105 mg/mL(199.29 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1